Giovanna Mirone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Giovanna Mirone has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Gabriella Marfe
Biologiche e Farmaceutiche, Second University of Naples
3 shared publicationsStefania Perna
Biologiche e Farmaceutiche, Second University of Naples
3 shared publications- Arvind Kumar Shukla
School of Biomedical Convergence Engineering, Pusan National University, Yangsan 50612, Republic of Korea
2 shared publications Carla Di Stefano
Department of Hematology; “Tor Vergata” University; Viale Oxford 81 Rome 00133 Italy
1 shared publicationGabriella Maffei
Department of Biochemistry and Biophysics, Second University of Naples, via De Crecchio 7, Naples, 80138, Italy
1 shared publication
Latest Publications
- 8 November 2016
- Published by Springer Nature
- p. 27-107
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
- 8 November 2016
- Published by Springer Nature
- p. 27-107
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
- 1 January 2016
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 97, 85-95
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
- 1 January 2016
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 97, 85-95
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
- Retracted
- 30 September 2015
- Published by Wiley in Journal of Cellular Physiology
- Vol. 231 (5) , 1097-1105
RETRACTED: Involvement of Notch‐1 in Resistance to Regorafenib in Colon Cancer Cells
Regorafenib, an oral small‐molecule multi kinase inhibitor, is able to block Vascular Endothelial Growth Factor Receptors (VEGFR‐1, 2, and 3), Platelet‐Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE‐2, and the kinases KIT, RET, and BRAF. Different studies have displayed its antitumor activity in several cancer models (both in vitro and in vivo), particularly in colorectal and gastrointestinal stromal cancers. The mechanism of resistance to regorafenib is largely unknown. In our investigation, we have generated regorafenib‐resistant SW480 cells (Reg‐R‐SW480 cells) by culturing such cells with increasing concentration of regorafenib. Examination of intracellular signaling found that Akt signaling was activated in Reg‐R‐SW480 cells but not in wild–type SW480 cells, after regorafenib treatment as measured by Western Blot. The Notch pathway is a fundamental signaling system in the development and homeostasis of tissues since it regulates different cellular process such as proliferation, differentiation, and apoptosis and it can be a potential driver of resistance to a wide array of targeted therapies. In this study, we found that Notch‐1 was significantly up‐regulated in resistant tumor cells as well as HES1 and HEY. Additionally, inhibition of Notch‐1 in resistant cells partially restored sensitivity to regorafenib treatment in vitro. Collectively, these data suggest a key role of Notch‐1 in mediating the resistant effects of regorafenib in colorectal cancer cells, and also provide a rationale to improve the therapeutic efficacy of regorafenib. J. Cell. Physiol. 231: 1097–1105, 2016.
- 30 September 2015
- Published by Wiley in Journal of Cellular Physiology
- Vol. 231 (5) , 1097-1105
RetractedRETRACTED: Involvement of Notch‐1 in Resistance to Regorafenib in Colon Cancer Cells
Regorafenib, an oral small‐molecule multi kinase inhibitor, is able to block Vascular Endothelial Growth Factor Receptors (VEGFR‐1, 2, and 3), Platelet‐Derived Growth Factor Receptors (PDGF), Fibroblast Growth Factor (FGF) receptor 1, Raf, TIE‐2, and the kinases KIT, RET, and BRAF. Different studies have displayed its antitumor activity in several cancer models (both in vitro and in vivo), particularly in colorectal and gastrointestinal stromal cancers. The mechanism of resistance to regorafenib is largely unknown. In our investigation, we have generated regorafenib‐resistant SW480 cells (Reg‐R‐SW480 cells) by culturing such cells with increasing concentration of regorafenib. Examination of intracellular signaling found that Akt signaling was activated in Reg‐R‐SW480 cells but not in wild–type SW480 cells, after regorafenib treatment as measured by Western Blot. The Notch pathway is a fundamental signaling system in the development and homeostasis of tissues since it regulates different cellular process such as proliferation, differentiation, and apoptosis and it can be a potential driver of resistance to a wide array of targeted therapies. In this study, we found that Notch‐1 was significantly up‐regulated in resistant tumor cells as well as HES1 and HEY. Additionally, inhibition of Notch‐1 in resistant cells partially restored sensitivity to regorafenib treatment in vitro. Collectively, these data suggest a key role of Notch‐1 in mediating the resistant effects of regorafenib in colorectal cancer cells, and also provide a rationale to improve the therapeutic efficacy of regorafenib. J. Cell. Physiol. 231: 1097–1105, 2016.
- 11 September 2014
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 116 (2) , 339-349
The Effects of Pyrrolo[1,2-b][1,2,5]Benzothiadiazepines in MEC1 Cells
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated antitumor activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepine (PBTDs) in MEC1 cells. We found that PBTD (RS2778) treatment enhanced the activation of pro-apoptotic members, such as caspase-9, 3, poly (ADP-ribose) polymerase (PARP), and bax, but suppressed the activation of anti-apoptotic molecule BCL-2 in these cells. Furthermore, PBTD (RS2778)-induced autophagic cell death was verified by LC3-II conversion, and upregulation of Beclin-1 and ATG5. In addition, such compound impeded hyper phosphorylation of AKT as were determined by Western blot. In summary, PBTD (RS2778) inhibited viability and induced multiple cellular events including apoptosis, autophagic cell death, in human MEC1 cells. This distinct activity of PBTD (RS2778) against these cells suggests potential for PBTDs as a therapeutic agent for treatment of CLL. J. Cell. Biochem. 116: 339–349, 2015.
- 11 September 2014
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 116 (2) , 339-349
The Effects of Pyrrolo[1,2-b][1,2,5]Benzothiadiazepines in MEC1 Cells
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated antitumor activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepine (PBTDs) in MEC1 cells. We found that PBTD (RS2778) treatment enhanced the activation of pro-apoptotic members, such as caspase-9, 3, poly (ADP-ribose) polymerase (PARP), and bax, but suppressed the activation of anti-apoptotic molecule BCL-2 in these cells. Furthermore, PBTD (RS2778)-induced autophagic cell death was verified by LC3-II conversion, and upregulation of Beclin-1 and ATG5. In addition, such compound impeded hyper phosphorylation of AKT as were determined by Western blot. In summary, PBTD (RS2778) inhibited viability and induced multiple cellular events including apoptosis, autophagic cell death, in human MEC1 cells. This distinct activity of PBTD (RS2778) against these cells suggests potential for PBTDs as a therapeutic agent for treatment of CLL. J. Cell. Biochem. 116: 339–349, 2015.